Health
Novel breast cancer therapy candidate enters clinical study – Mirage News
Kiran Dhillon In a UW Medicine cancer immunotherapy lab, research scientist Nick Drovetto puts a rack of samples into a liquid nitrogen tank. A Phase 1…
A Phase 1 patient trial of the novel, oral therapy candidate, Alpha TEA, for advanced HER2 positive breast cancer is now underway. Veana Therpeutics, Inc., and UW Medicine will collaborate on the clinical testing of Veana’s lead agent – an alpha TEA lysine salt, in combination with the monoclonal antibody, trastuzumab, brand name Herceptin.
In HER2 positive breast cancer, the tumor cells produce a higher-than-usual level of the HER2protein that drives cancer growth and spread.
Alpha TEA lysine…
-
General13 hours agoARIA Awards 2025 winners: Amyl & The Sniffers and Ninajirachi dominate
-
Noosa News22 hours agoChild, 15, arrested over death of another child, 8, after shocking e-bike crash in Queensland
-
Noosa News13 hours agoPolice officer who tracked Toyah Cordingley’s phone gives evidence at Rajwinder Singh’s murder trial
-
Noosa News20 hours agoDeath of German shepherd Arnie prompts Brisbane community action to protect pets caught up in crime